Editorial p 1830
We conducted the MIRACLE-ICD Outcome Measured in Japanese Indication (MOMIJI) Study to compare the efficacy of CRT-D therapy in a population of Japanese patients with advanced HF, an intraventricular conduction delay, and an indication for implantable cardioverter defibrillator (ICD) therapy. The aim of the study was to examine the non-inferiority to the results of the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) general phase study conducted in the United States with regard to a composite clinical response (CCR) that classified patients as being improved, unchanged, or worsened. The MOMIJI study is the first prospective multicenter clinical trial of CRT-D therapy in an allJapanese population seeking to evaluate equivalency of therapy to that in Western countries and the first usage of the officially validated Japanese language version of the Minnesota Living with Heart Failure (MLHF) questionnaire.
Methods

Study Population
The MOMIJI study was conducted at 22 centers in Japan between March 12, 2007 and March 31, 2009 . Enrollment criteria were similar to those of the MIRACLE-ICD study, 1 except for left ventricular end-diastolic diameter (LVEDD) ≥55 mm and 6-min walk distance >450 m, which were an inclusion and an exclusion criterion, respectively, for MIRACLE-ICD. Table 1 lists the inclusion and exclusion criteria. No particular medications were required, and the medication status of patients was collected at baseline. The study protocol was approved by the institutional review board/medical ethics committee of each participating center, and all patients provided signed informed consent.
Patients meeting the enrollment criteria underwent a baseline evaluation prior to implant that included New York Heart Association (NYHA) class assessment, echocardiography, most recent documented intrinsic QRS interval, and B-type natriuretic peptide (BNP) measurement. Patients were also asked to complete 2 QOL assessment tools: the MLHF questionnaire in the Japanese language and the Specific Activity Scale (SAS) questionnaire. Patients then underwent implantation of a com- (A) Indicated heart failure patients:
• NYHA class III or IV
• LVEF ≤35%
• Intrinsic QRS duration ≥130 ms (B) Patients with one of the following risks for sudden cardiac death:
• History of resuscitation from cardiac arrest following fatal arrhythmia (clear loss of consciousness)
• VT or VF that disrupts hemodynamics
• Confirmed NSVT, as well as VT or VF induced by electrophysiological testing (C) Patients who meet the Japanese criteria for implantation of an ICD 3. Patients signed the informed consent and permission for access to and use of health information. 10. Chronic AF defined using the following classification:
• Permanent: long-standing episode for which cardioversion did not take effect.
• Persistent: recurrent episodes that are sustained but could be cardioverted.
• Paroxysmal: recurrent episodes that stopped spontaneously.
11. Heart transplant recipient 12. Severe valvular heart disease (decision on severity made by a medical doctor) 13 . Existing CRT or CRT-D device NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia; VF, ventricular fibrillation; ICD, implantable cardioverter defibrillator; AF, atrial fibrillation; CRT, cardiac resynchronization therapy; CRT-D, CRT with an implantable cardioverter defibrillator. CRT in a Japanese Population mercially available CRT-D device manufactured by Medtronic, Inc (Minneapolis, MN, USA) and a right atrial pacing lead, a right ventricular pacing/defibrillator lead, and a left ventricular lead. A variety of leads not limited to those manufactured by Medtronic were used in the study.
Device Programming
General device programming was left to physician discretion. However, optimization of the sensed and paced atrioventricular (AV) delays was required. Use of the Ritter Method 16 was encouraged though other methods were allowed. Interventricular (V-V) timing optimization was recommended, and was required to be performed prior to AV delay optimization. Additionally, programming antitachycardia pacing (ATP) according to the PainFREE Rx II algorithm was recommended. 17
Study Design and Endpoints
The MOMIJI study was a prospective, multicenter, observational study characterizing outcomes of CRT-D therapy in a Japanese population. The primary endpoint was non-inferiority to the CCR seen in the general phase of the MIRACLE-ICD study. The CCR was a secondary endpoint in both the intensive and general phases of the MIRACLE-ICD study. The CCR, which assesses patients more globally, is an accepted outcome measure in HF trials and has been used as an endpoint in studies such as the MIRACLE-ICD II and Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) studies. 4-6, 18 Patients in the MOMIJI study were classified as worsened, improved, or unchanged using definitions of those in the MIR-ACLE-ICD study. In the MOMIJI study, a patient was classified as worsened if he or she died, was hospitalized due to or associated with worsening HF, permanently discontinued CRT-D due to or associated with worsening HF, treatment failure, or lack of/insufficient therapeutic response, withdrew or was withdrawn from study and had worsening HF at the time of study withdrawal; demonstrated worsening in NYHA class at last observation carried forward (LOCF) or moderate-marked worsening of patient global assessment score at LOCF. Only hospitalizations that were due to worsening HF and would have resulted in the patient being hospitalized under standard medical practice were included in the CCR analysis. To minimize bias in comparison of hospitalization data between the MOMIJI and MIRACLE-ICD studies, a hospitalization events review committee composed of Japanese and US HF physicians adjudicated hospitalizations to determine if a Japanese admission would have been managed on an outpatient basis had the case been managed in the USA or if the patient would have been hospitalized. A patient was classified as improved if he or she had not worsened (as defined above) and demonstrated improvement in NYHA class at LOCF and/or moderate to marked improvement in patient global assessment score at LOCF. A patient was unchanged if he or she was neither improved nor worsened.
Secondary outcomes in the MOMIJI study included QOL assessment using the MLHF and SAS. The MLHF questionnaire is a validated 19,20 and well established assessment tool that has been used to assess patient QOL in a number of major trials of CRT. 1,5,6,21, 22 The Japanese translation of the MLHF questionnaire was validated linguistically by the Health Outcome Group (San Francisco, CA, USA) with permission from Minnesota University (Minneapolis, MN, USA). The SAS assessment tool 23 is recommended by the Japanese Circulation Society and is widely used in Japan. Other secondary outcomes included characterization of the effectiveness of ATP in terminating ventricular tachycardia (VT) episodes and plasma BNP levels, echocardiographic parameters, and HF hospitalizations. The mitral regurgitant fraction was assessed by calculating the percentage of the color-Doppler area relative to the left atrial area in the apical 4-chamber view. Patients were followed at 1, 3, and 6 months. Full interrogation of the CRT-D device and NYHA assessment were performed at each visit. QOL evaluation using the MLHF and SAS questionnaires and echocardiography were performed at 6-month follow-up only.
MIRACLE-ICD General Phase
The general phase of the MIRACLE-ICD study was a continuation of the intensive phase which evaluated the safety and efficacy of the Medtronic Model 7272 InSync ICD system. All patients were programmed to CRT ON and both physicians and patients were unblinded to therapy delivery. Study inclusion and exclusion criteria were the same as in the intensive phase. 1 The general phase of the MIRACLE-ICD study was chosen as a comparative reference point for the therapeutic efficacy of CRT-D in the MOMIJI study because the inclusion criteria were similar to the CRT-D indication in Japan and because the study was unblinded. The intensive phase of the MIRACLE-ICD study was a prospective randomized doubleblind study during which both physicians and patients were unaware of whether CRT was turned ON or OFF. 1 Results of the general phase of the MIRACLE-ICD study have not been published previously. However, the study authors have granted the MOMIJI investigators full access to the data and permission to publish the results of the general phase of the MIRACLE-ICD study as needed.
Statistical Analysis
All successfully implanted patients were included in the analysis. In terms of the primary endpoint, 62% (88/142) of the patients with NYHA class III or IV in the MIRACLE-ICD study had a response of improved on the CCR. We evaluated the non-inferiority with an equivalent margin of 10% on the CCR and a P-value <0.05 using an exact proportion test. An odds ratio analysis with and without a propensity score was also performed. The propensity score was computed using logistic regression with the study (MIRACLE-ICD or MOMIJI) as a response variable and 13 baseline parameters (sex, age, NYHA class (III or IV), QRS duration, left ventricular ejection fraction (LVEF), LVEDD, non-ischemic or ischemic etiology, hypertension, angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, and diuretic) as explanatory variables. The odds ratio and 95% confidence interval (CI) of improved CCR between both studies were calculated directly and with the adjusted quintile propensity score.
For the secondary endpoints, descriptive statistics were used. The paired t-test was used to compare changes from baseline to 6 months. The success rate of ATP therapy was analyzed using detected VT/ventricular fibrillation (VF) episodes treated by ATP. ATP was considered successful if the episode terminated prior to a cardioversion or defibrillation shock. Geometric means were used for the analysis of BNP.
Adverse events were not collected. However, centers were required to report events in the same manner required for any commercially available device in Japan. The study was coordinated by Medtronic Japan. All data were collected on case report forms. Information was forwarded via a DataFax system and automatically stored into a database. Device interrogation data were saved to disk and forwarded to Medtronic Japan.
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Results
Through August 31, 2008, 93 patients were enrolled in the MOMIJI study. Of these patients, 13 were withdrawn (7 patients did not meet the eligible criteria for this study; 3 patients underwent an implant attempt but a device was not implanted; 2 patients had their device explanted; and 1 patient died prior to implantation). The remaining 80 patients comprise the MO-MIJI study population described in this report. The baseline characteristics of the patients in the MOMIJI and the MIRA-CLE-ICD general phase are summarized in Table 2 . There was a significant difference (P<0.05) between the 2 populations in terms of LVEF and the percentage of patients with an ischemic etiology, hypertension, non-sustained VT, and antiarrhythmic drugs. For all other baseline categories, the clinical characteristics of patients in both studies were similar.
Primary Endpoint
CRT-D treatment exerted favorable effects on the CCR. At 6-month follow-up, CCR was improved in 68.8% (n=55), unchanged in 17.5% (n=14), and worsened in 13.8% (n=11). These results demonstrated the non-inferiority compared with the MIRACLE-ICD general phase data (Figure 1) . The difference in the percentage of patients improved at 6-month follow-up was 6.78 (95% CI: −6.14 to 19.70). Non-inferiority was verified by 1-sided test with the equivalent margin of 10% (P=0.01). Non-inferiority with the MIRACLE-ICD CCR was also confirmed in the odds ratio analysis to adjust for the differences in the baseline characteristics between 2 studies. For improved CCR, the unadjusted odds ratio between MIRACLE-ICD and MOMIJI was 1.350 (95% CI: 0.755 to 2.415, P=0.3119). The odds ratio adjusted by propensity score was 1.309 (95% CI: 0.684 to 2.507, P=0.42). These odds ratios were comparable, and both lower interval values were greater than 0.668 dem- Table 1 . CRT in a Japanese Population onstrating lower limit corresponding to the non-inferiority margin of 10%.
Secondary Endpoints
The results of the secondary endpoints are summarized in Table 3 . The improvement with MLHF scores between the baseline visit and 6-month follow-up were comparable to those seen with MIRACLE-ICD study (Figure 2) . SAS scores also improved significantly confirming that the QOL of the patients were enhanced. Significant improvements were also observed with echocardiographic parameters as well as with the BNP level.
Arrhythmic Events
During the 6-month study period, a total of 80 episodes of VT (cycle length (CL): >320 ms) or fast VT (FVT, CL: 240-320 ms) were detected in 11 patients. Of these episodes, 50 were appropriate detections and 30 were inappropriate detections. Atrial tachycardia (AT) or atrial fibrillation was the reason for inappropriate detections in 15 (50%) of the total inappropriate detections, and the remaining supraventricular tachycardia was the reason for the other 15 (50%). A total of 5 patients experienced inappropriate detections with 3 patients experiencing 20 shocks. Considering the appropriate detections, 8
patients experienced a total of 50 episodes of VT or FVT. Of these episodes, 48 (96.0%) were VT and 2 were FVT (4%). Two FVT episodes occurred in 1 patient and were terminated with a total of 3 shocks. The efficacy of ATP is shown in Figure 3 . ATP was attempted in a total of 48 VT episodes and successfully terminated 79.2% (n=38) on the first attempt. In all, ATP was successful in 93.8% of the episodes (n=45) (Figure 3) . The efficacy of ATP by CL is shown in Figure 4 . ATP was successful in 100% of episodes with CLs >360 ms and in 81% of episodes with CLs from 320 to 360 ms.
HF Hospitalization and Deaths
There were 12 HF-related hospitalizations in 10 patients during the study. Adjudication by the Hospitalization Events Review Committee composed of 3 Japanese and 2 US HF specialists concurred that 4 (33.3%) of the HF hospitalizations would not have occurred if US practice guidelines had been applied. A total of 4 patients died during the follow-up period: 3 patients died due to progressive HF and 1 due to pneumonia. Figure 1 . Clinical composite response in MOMIJI (n=80) and MIRACLE-ICD general phase (n=142) patients. There was a 6.8% (SD 6.59%) difference in the proportion that improved between the MOMIJI study and the MIRACLE-ICD general phase study. The 95% confidence interval was −6.14 to 19.70, demonstrating a non-inferiority margin of more than −10%. Tables 1,2. 1916 MOMOMURA S et al.
Discussion
The improvements in the CCR observed in the MOMIJI study were non-inferior to those in the MIRACLE-ICD general phase.
Compared with the patients in the MIRACLE-ICD study, those in the MOMIJI study had a higher LVEF, a higher proportion of non-ischemic cardiomyopathy and history of hypertension, and a higher rate of antiarrhythmic drug prescription. However, non-inferiority of the CCR was confirmed in the MO-MIJI study after adjustment of these differences of baseline characteristics between the studies with propensity score analysis.
The results in the CCR score in the MOMIJI study were also similar to those in the PROSPECT study, which also assessed the performance of CRT in a predominately NYHA class III population (96% in the PROSPECT vs. 88.7% in the MOMIJI study) conducted in 53 centers in Europe, Hong Kong, and the USA. 18 In the PROSPECT study, the clinical composite score improved in 69% of 426 patients at 6-month followup compared with 68.8% in MOMIJI. This finding strengthens the evidence that the benefits of CRT observed in Western patients are transferable to Japanese patients with similar indications.
The morbidity and mortality benefits of CRT have been documented in prior large-scale landmark trials, however, Japanese patients were not included in the creation of this clinical evidence. The randomized controlled Cardiac Resynchronization-Heart Failure (CARE-HF) study, which included 813 patients with NYHA III or IV HF at 82 centers in Europe and a mean follow-up of 29.4 months, established the mortality benefit of CRT. 3 The CARE-HF study supported the recommendation that CRT devices should be considered in indicated patients to improve their prognosis. More recently, the efficacy of CRT and CRT-D has been studied in patients with less severe HF (NYHA class I and II). The European cohort of the REVERSE study demonstrated that CRT improved the CCR in a total of 287 patients from 35 European centers at 24 months. 5 The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) of 1,798 patients in Canada, Europe, Turkey, and Australia with NYHA class II or III HF and a mean follow-up of 40 months found that CRT-D therapy resulted in a 25% reduction in the relative risk of death and in In terms of QOL evaluation, the MOMIJI study represents the first use of the MLHF questionnaire validated for Japanese patients. As such it provides a valuable assessment tool in studies examining the effects on patient QOL of various therapeutic modalities including CRT and CRT-D. MLHF score, a secondary endpoint in the MOMIJI and MIRACLE-ICD general phase, decreased in both studies, demonstrating improved QOL by CRT-D. MLHF score was a primary endpoint in the MIRACLE study, and patients receiving CRT demonstrated improvements at 6-month follow-up compared with the control group (median changes −18 vs. −9, P=0.001). 21 In the PATH-HF study, QOL score was unchanged in patients receiving CRT compared with univentricular pacing (25.2±3.3, 28.1±3.5, P=0.069); however, the follow-up period was very short. 22 The MOMIJI study also evaluated cardiac functional parameters, which significantly improved as in the Western studies ( Table 3) . Although we could not perform statistical comparisons between them, the change in LVEF appeared to have improved more in the present patient population when compared with patients enrolled in the MIRACLE-ICD intensive phase 1 (median LVEF absolute change at 6 months +6.0% vs. +2.1%, respectively). This might be due to the higher proportion of non-ischemic patients among the MOMIJI study patients than that of the MIRACLE-ICD intensive phase (70.0 vs. 36.0%, P<0.01). Of note, the degree of LV reverse remodeling has been shown to be greater in non-ischemic than ischemic patients. 24, 25 On the other hand, the mean changes in BNP at 3 months were comparable between the MOMIJI and the CARE-HF 3 studies: −186 pg/ml (95% CI: −366 to −7 pg/ml) and −225 pg/ml (95% CI: −705 to 255 pg/ml), respectively.
Among other secondary endpoints, the MOMIJI study examined the efficacy of ATP to terminate VT and prevent unnecessary defibrillation shocks. There were 50 episodes of ventricular tachyarrhythmia in 8 patients in the MOMIJI study, and the incidence rate was lower than that of MIRACLE-ICD intensive phase (10 vs. 22%, P=0.02). 1 One explanation could be that the patients in the MOMIJI study were prescribed antiarrhythmic drug more frequently than those in the MIRA-CLE-ICD intensive phase (52.5 vs. 32.4%, P<0.01). In the MOMIJI study, 93.8% of treated VT or FVT episodes were successfully terminated with ATP without the need for shocks. A lower incidence of shocks could improve QOL and increase the acceptability and tolerability of ICD therapy without compromising efficacy. Several studies have found that patients receiving defibrillation shocks have rather an increased mortality risk even though ICDs could terminate life-threatening ventricular arrhythmias. 26-28 Defibrillation shocks may cause myocardial damage and have negative inotropic effects, and those patients may be more susceptible to harm from shocks. 29-31 A combination of known and unknown factors may be involved, requiring further study to elucidate.
The MOMIJI study, which confirmed the therapeutic noninferiority to the MIRACLE-ICD study conducted in North America, advances the need of CRT-D therapy based on the broader clinical experience.
Study Limitations
First, the number of analyzed patients was as few as 80 in the MOMIJI study. In addition, the non-inferiority of the present analysis was based on a comparison between the MOMIJI and MIRACLE-ICD general phase populations. Therefore, the differences in baseline characteristics between them may have introduced bias into the results. However, non-inferiority was confirmed by the propensity score. Therefore, we consider that the non-inferiority was meaningful in this study. Second, the prescription rate of β-blockers might be relatively low in light of current clinical practice and may have affected the results of this study; 32 however, there were no statistical difference between the MIRACLE-ICD study and the MOMIJI study with respect to the prescription rate. Third, the MOMIJI study was not designed or powered to detect mortality or morbidity difference and the follow-up period of 6 months may have been too short to detect the effects of CRT-D on cardiac function and QOL.
Conclusions
The MOMIJI study demonstrated the non-inferiority of the clinical efficacy of CRT-D in Japanese patients compared with a similar trial conducted in the USA. The results suggest that the benefits of CRT-D previously demonstrated in Western patient populations can be extrapolated to Japanese patients.
